Aptorum Group Ltd - Ordinary Shares - Class A

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop drug molecules and certain technologies for the treatment and diagnosis of human disease conditions. The Non-Therapeutics segment encompasses diagnostics projects including a novel molecular-based rapid pathogen identification and detection diagnostics, AML Clinic, and sale of natural supplements. Its pipeline include Smart-Act, Acticule, RPIDD, Nativus, and Claves series. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #CTAsubmission--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to cond

Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced the results of its 2020 annual general meeting of shareholders, which was held on December 9, 2020, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: re-elected all

Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders

Aptorum Group has competition in the rapid pathogen identification and detection diagnostics (RPIDD) field. Is APM stock the best bet?

Is Aptorum Group the Best Buy Among Its Peers?

Aptorum Group got a boost when the company jumped into the Covid-19 conversation. APM stock looks like a late entry into crowded field.

Don't Get Swept Up In the Unproven Promise of Aptorum Group

APM stock is a risky name, but the company's recent deal with Singapore has potentially given it a huge opportunity in Asia. The post Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy appeared first on InvestorPlace.

Why Aptorum's New Singapore Deal Makes It a Worthwhile Buy

APM stock remains a highly speculative bet for investors as the small biotech company comes with significant risk and volatility. The post Aptorum Group Is Risky, Despite Popularity appeared first on InvestorPlace.

Aptorum Group Is Risky, Despite Popularity

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the “Company”, “Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced it will hold its 2020 annual general meeting of shareholders at its Hong Kong office located at 17/F, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong at 8:00 p.m. Hong Kong Time on December 9, 2

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020

APM stock mostly flew under the radar among biotechnology investors. After a recent price surge, though, the stock is now an attention getter.

This Covid-19 Connection Makes Aptorum Group Stock Intriguing

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced the closing of a public offering of 2,769,231 Aptorum’s Class A ordinary shares (or ordinary share equivalents) and warrants to purchase up to 2,769,231 Class A Ordinary Shares, at a combined public offering price of $3.25 per share and related w

Aptorum Group Announces Closing of $9.0 Million Public Offering

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced the pricing of a public offering of 2,769,231 Aptorum’s Class A ordinary shares (or ordinary share equivalents) and warrants to purchase up to 2,769,231 Class A Ordinary Shares, at a combined public offering price of $3.25 per sh

Aptorum Group Announces Pricing of $9.0 Million Public Offering

Aptorum Group Ltd. (NASDAQ: APM) shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases. Although this company isn’t a household name, it was catching a lot of attention Tuesday.

Why Aptorum Stock Absolutely Took Off on Tuesday

Aptorum Group Ltd (NASDAQ: APM) shares are skyrocketing Tuesday following an announcement concerning the setting up of a subsidiary focused on diagnostic testing.
 What Happened:  U.K.-based Aptorum that focuses on developing therapies primarily for infectious diseases and cancer said it's launching Aptorum Innovations, an infectious liquid biopsy diagnostics subsidiary.

Aptorum Soars 800% On Diagnostic Testing Launch

APM stock is soaring on news that Aptorum Group is launching a subsidiary focused on liquid biopsies for infectious diseases. 
The post APM Stock: Why Aptorum Group Is Soaring 500% Today appeared first on InvestorPlace.

APM Stock: Why Aptorum Group Is Soaring 500% Today

NEW YORK, LONDON, & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum Innovations - an infectious disease liquid biopsy diagnostics subsidiary and its newly established exclusive in-licensing arrangements with Accelerate Technologies Pte Ltd (“Accelerate Technologies”), commerci

Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome

NEW YORK--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced an interview with its President, Daniel Lui, will air on The RedChip Money Report television program. The interview will air Sunday, August 30, at 6 p.m.

Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report

NEW YORK--(BUSINESS WIRE)-- #euronextlisting--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs, today is pleased to announce that its Class A Ordinary Shares has commenced trading on the Professional Compartment of Euronext in Paris under the Euronext ticker symbol “APM” and ISIN Code: KYG6096M1069. Aptorum Group’s Class A Ordinary Shares continues to be listed on the Nasdaq Gl

Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM

NEW YORK--(BUSINESS WIRE)-- #Euronext--Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs, today is pleased to announce that the French Autorité des Marchés Financiers (“AMF”) has granted visa number 20-352 on its prospectus in respect of its fast path cross-listing of its Class A Ordinary Shares (the “Shares”) on the Professional Compartment of Euronext in Paris. The Comp

News for Aptorum Group Ltd - Ordinary Shares - Class A Stock (APM)